Posaconazole
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clinical Infection
Conditions
Clinical Infection
Trial Timeline
Dec 1, 2013 → —
NCT ID
NCT02020213About Posaconazole
Posaconazole is a approved stage product being developed by Merck for Clinical Infection. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02020213. Target conditions include Clinical Infection.
What happened to similar drugs?
0 of 3 similar drugs in Clinical Infection were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00686621 | Pre-clinical | Completed |
| NCT05065658 | Pre-clinical | Completed |
| NCT03318159 | Phase 2 | Completed |
| NCT03336502 | Phase 1 | Completed |
| NCT02387983 | Phase 1 | Completed |
| NCT02020213 | Approved | Withdrawn |
| NCT00811642 | Phase 3 | Completed |
| NCT00686543 | Approved | Completed |
| NCT00550732 | Phase 2 | Completed |
| NCT00726609 | Pre-clinical | Completed |
| NCT00034658 | Phase 3 | Completed |
Competing Products
20 competing products in Clinical Infection